News of blood-testing startup from entrepreneur Billy Evans sparks shock, anger, and skepticism.

May 12, 2025 Check out STAT+

Sponsored By

STAT's Breakthrough Summit West is happening this Wednesday in San Francisco — do you have your ticket yet? View the agenda and register for in-person or virtual access.

Philip Pacheco/Getty Images Elizabeth Holmes rises again — or at least her partner does Holmes, serving an 11-year sentence, has no official role in Billy Evans biotech startup Haemanthus. Firm says it's not "Theranos 2.0," experts skeptical. By Casey Ross and Jonathan Wosen STAT+ | White House unveils sweeping plan to try to lower U.S. drug prices Trump presses 'most-favored nation' policy, leaves door open to more importation of medicines By Daniel Payne Beyond politics, even U.S. vaccine experts may envision fewer Covid shots in the future HHS Secretary Robert F. Kennedy Jr. and his aides have indicated they believe far fewer people should be urged to get Covid shots. CDC advisers may agree. By Helen Branswell DANIEL SLIM/AFP via Getty Images Amid the Milwaukee lead crisis, a laid-off CDC scientist volunteered his expertise. It wasn't so simple Lead prevention expert, laid off in recent CDC cuts, volunteered to help with lead contamination in Milwaukee schools By Eric Boodman STAT+ | Chinese and Chinese-American researchers in the U.S. confront a perilous moment Chinese, Chinese-American researchers see disproportional impact due to high representation among NIH-funded scientists. Some now looking at work overseas. By Brian Yang STAT+ | House GOP unveils plans to reshape Medicaid Ahead of a mark-up this week, the House GOP laid out plans to reduce Medicaid spending as it seeks to offset the cost of planned tax cuts. By John Wilkerson Adobe Opinion: Science is under attack. So I'm taking RFK Jr. to court Harvard's Brittany Charlton, in STAT First Opinion essay, explains why she sued RFK Jr. over defunded LGBTQ+ programs: "It's about science and democracy." By Brittany Charlton STAT+ | Trump's drug-pricing order takes a hard line against pharma. Investors shrugged The markets appeared unconvinced that a "most-favored nation" plan, as outlined in a new executive order, will ever take effect. By Elaine Chen STAT+ | OpenAI leaps into health care with AI benchmark to evaluate models The company's foray into the field was welcomed by experts, but some cautioned that the effort is not comprehensive and may need further analysis. By Brittany Trang

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Daily Recap? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser